The Anglo-Swedish pharmaceutical company, AstraZeneca, has strike a deal with the Medical Research Council. As per this deal, they would allow MRC to access their 22 chemical compounds to design some of the best treatments for range of diseases.

Brain disorders were definitely not less troubling for many families that a new problem has arisen to make the things more complicated for the people. This time drug firms have lead the threat as they have decided to pull out from the researches regarding brain disorder, which can definitely affect many severely and moreover, will also have a big financial impact on the society.

Astra Zeneca PLC (AZN. LN) a global bio pharmaceutical company which has the primary focus on the discovery, development and commercialization of prescription medicines, said that its one of the units MedImmune had received notice that the US food and drug Administration has reset the date of its review of motavizunab to 27th August.

Following the failure of its experimental cancer drug Recentin in treatment of colon cancer reported in a study on Friday, AstraZeneca has decided to terminate its further production.

It has removed the drug as the firstline product for the cancer cure.

The failure was received as a shock by a number of experts as well as the Company.

Before approving Certriad cholesterol drug for sale, AstraZeneca PLC and Abbott Laboratories stated that more information on the drug has been asked by the U.S. Food and Drug Administration.

The FDA sent a complete response letter in which more data regarding their new drug application, which combines their cholesterol pills TriLipix and Crestor has been sought.